Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.33 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 5/20 | 0.32 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | ROS1 | P08922 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220468 | 0.89 | F10 (0.48) | F10ALDH1A1SMYD3ACKR3DPP4 | |
| Fumaric Acid SCHEMBL3873520 | 0.85 | F10 (0.42) | F10ALDH1A1ACKR3HRH3CYP2D6 | |
| SCHEMBL222294 | 0.81 | F10 (0.46) | F10ALDH1A1SMYD3ACKR3DPP4 | |
| SCHEMBL3872404 | 0.79 | F10 (0.50) | F10ALDH1A1SMYD3ACKR3DPP4 | |
| SCHEMBL13102745 | 0.76 | F10 (0.49) | F10ALDH1A1ACKR3HRH3CYP2D6 | |
| SCHEMBL3875128 | 0.75 | F10 (0.46) | F10ALDH1A1SMYD3ACKR3DPP4 | |
| SCHEMBL3872691 | 0.74 | F10 (0.34) | F10SMYD3 | |
| SCHEMBL10218749 | 0.74 | F10 (0.46) | F10ALDH1A1SMYD3ACKR3HRH3 | |
| Fumaric Acid SCHEMBL221972 | 0.73 | F10 (0.89) | F10 | |
| SCHEMBL223223 | 0.72 | F10 (0.49) | F10ALDH1A1HRH3CYP2D6KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888567-B1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1888567-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis (FR) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122661-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | TFPI, SERPINC1, PLAT | DPP4 1599/4885HRH3 2835/4885FLT3 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.